首页 > 最新文献

Oncology Research and Treatment最新文献

英文 中文
Ambulatory Routine Care in Oncology in Germany: Real-World Survival Data. 德国非住院常规肿瘤治疗:真实世界的生存数据。
IF 2 4区 医学 Q3 ONCOLOGY Pub Date : 2024-01-01 Epub Date: 2024-03-15 DOI: 10.1159/000536652
Norbert Marschner, Wolfgang Knauf

Introduction: Survival data reported by randomised controlled trials are collected in a highly selected patient population and can thus only be transferred to a limited extent to real-world patients: the patients in routine care are mostly older, present with more comorbidities and a worse general state of health. This so-called efficacy-effectiveness gap typically results in inferior survival data in routine healthcare.

Methods: Six prospective clinical tumour registries recruited a total of 11,679 patients receiving systemic therapy in haemato-oncological practices in Germany between 2006 and 2020. For these patients with advanced colorectal cancer, breast cancer, lung cancer, pancreatic cancer, renal cell cancer, and lymphatic neoplasms, overall survival was analysed. A comprehensive literature search was performed to identify suitable pivotal randomised controlled trials.

Results: Median overall survival of patients treated in German routine care, with advanced colorectal, breast, lung, and pancreatic cancer, as well as with diffuse large B-cell lymphoma and multiple myeloma, is not shorter than the respective survival data reported in trials. Patients with advanced renal cell carcinoma, chronic lymphocytic leukaemia, or indolent non-Hodgkin lymphoma showed slightly lower survival rates compared to clinical trials.

Conclusions: Despite less favourable patient characteristics, survival data from patients with cancer treated in ambulatory routine care in Germany are in range with results from randomised controlled studies.

简介随机对照试验报告的存活率数据是在经过严格筛选的患者群体中收集的,因此只能在一定程度上应用于现实世界中的患者:常规护理中的患者大多年龄较大,合并症较多,总体健康状况较差。这种所谓的疗效差距通常会导致常规医疗的生存数据较差:方法:2006 年至 2020 年间,六个前瞻性临床肿瘤登记处共招募了 11679 名在德国血液肿瘤诊所接受系统治疗的患者。对这些晚期结直肠癌、乳腺癌、肺癌、胰腺癌、肾细胞癌和淋巴肿瘤患者的总生存期进行了分析。为了找到合适的关键性随机对照试验,我们进行了全面的文献检索:结果:在德国接受常规治疗的晚期结直肠癌、乳腺癌、肺癌、胰腺癌以及弥漫大 B 细胞淋巴瘤和多发性骨髓瘤患者的中位总生存期并不比试验报告的相应生存期数据短。与临床试验相比,晚期肾细胞癌、慢性淋巴细胞白血病或非霍奇金淋巴瘤患者的生存率略低:结论:尽管患者的特征不太理想,但在德国接受非住院常规治疗的癌症患者的生存数据与随机对照研究的结果相符。
{"title":"Ambulatory Routine Care in Oncology in Germany: Real-World Survival Data.","authors":"Norbert Marschner, Wolfgang Knauf","doi":"10.1159/000536652","DOIUrl":"10.1159/000536652","url":null,"abstract":"<p><strong>Introduction: </strong>Survival data reported by randomised controlled trials are collected in a highly selected patient population and can thus only be transferred to a limited extent to real-world patients: the patients in routine care are mostly older, present with more comorbidities and a worse general state of health. This so-called efficacy-effectiveness gap typically results in inferior survival data in routine healthcare.</p><p><strong>Methods: </strong>Six prospective clinical tumour registries recruited a total of 11,679 patients receiving systemic therapy in haemato-oncological practices in Germany between 2006 and 2020. For these patients with advanced colorectal cancer, breast cancer, lung cancer, pancreatic cancer, renal cell cancer, and lymphatic neoplasms, overall survival was analysed. A comprehensive literature search was performed to identify suitable pivotal randomised controlled trials.</p><p><strong>Results: </strong>Median overall survival of patients treated in German routine care, with advanced colorectal, breast, lung, and pancreatic cancer, as well as with diffuse large B-cell lymphoma and multiple myeloma, is not shorter than the respective survival data reported in trials. Patients with advanced renal cell carcinoma, chronic lymphocytic leukaemia, or indolent non-Hodgkin lymphoma showed slightly lower survival rates compared to clinical trials.</p><p><strong>Conclusions: </strong>Despite less favourable patient characteristics, survival data from patients with cancer treated in ambulatory routine care in Germany are in range with results from randomised controlled studies.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"340-350"},"PeriodicalIF":2.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11251673/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140143891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Contents Vol. 46, 2023 目录46, 2023
IF 2.4 4区 医学 Q3 ONCOLOGY Pub Date : 2023-12-01 DOI: 10.1159/000535561
J. P. Klussmann, Marcus Schmidt, Matthias Theobald – Third, Peter Albers, Dirk Arnold, D’Andrea, M. A. Reddy, TX G.K. Houston, Therapeutischer Ansatzpunkt, Immunsystem
{"title":"Contents Vol. 46, 2023","authors":"J. P. Klussmann, Marcus Schmidt, Matthias Theobald – Third, Peter Albers, Dirk Arnold, D’Andrea, M. A. Reddy, TX G.K. Houston, Therapeutischer Ansatzpunkt, Immunsystem","doi":"10.1159/000535561","DOIUrl":"https://doi.org/10.1159/000535561","url":null,"abstract":"","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":"1 3","pages":"548 - 555"},"PeriodicalIF":2.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139021269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AbbVie: BioPharma-Unternehmen mit onkologischer Mission 艾伯维:肩负肿瘤使命的生物制药公司
IF 2.4 4区 医学 Q3 ONCOLOGY Pub Date : 2023-12-01 DOI: 10.1159/000535453
Pflichttext Epcoritamab, Pflichttext Venetoclax
{"title":"AbbVie: BioPharma-Unternehmen mit onkologischer Mission","authors":"Pflichttext Epcoritamab, Pflichttext Venetoclax","doi":"10.1159/000535453","DOIUrl":"https://doi.org/10.1159/000535453","url":null,"abstract":"","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":"773 ","pages":"I - VIII"},"PeriodicalIF":2.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139024835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Large Brown Tumour of Mandible with Bleeding as Initial Presentation: A Case Report. 以出血为首发表现的下颌骨大棕色肿瘤1例。
IF 0.6 4区 医学 Q3 ONCOLOGY Pub Date : 2023-12-01 Epub Date: 2023-06-30 DOI: 10.1007/s12070-023-04003-w
Ajinkya Pawar, Priyank Rathod, Jebin Aaron, Vivek Bande, Kanika Kapur

Brown Tumour or Osteitis fibrous cystic or Von-Recklinghausen disease of bone is a non-malignant condition due to abnormal metabolism of bones in hyperparathyroidism. Although pathognomonic of hyperparathyroidism, brown tumours are rare and only case reports are found in literature. We report a case of brown tumour of mandible with recurrent episodes of bleeding. A 46 year old male patient presented in emergency with bleeding from ulceroproliferative mass from left floor of mouth. After control of bleeding, radiological, laboratory and histopathological investigations were done that led to the diagnosis of brown tumour of mandible in the presence of parathyroid adenoma of left lower parathyroid gland. Left upper and lower parthyroidectomy was done with segmental resection of mandible with mass and titanium plating. Brown tumour of facial bones is a rare entity. Very rarely it can reach enormous sizes to cause bleeding. Although parathyroidectomy and correction of parathormone levels cause regression of small tumours, large brown tumours with complications should be managed with surgical resection and reconstruction.

骨棕色瘤或骨性炎纤维囊性或Von-Recklinghausen病是甲状旁腺功能亢进患者骨代谢异常引起的一种非恶性疾病。虽然甲状旁腺功能亢进的病理特征,棕色肿瘤是罕见的,只有病例报告在文献中发现。我们报告一个棕色肿瘤的下颌骨与反复发作的出血。一位46岁男性病患因左口腔溃疡增生性肿块出血而急诊就诊。出血控制后,经影像学、实验室及组织病理学检查,诊断为下颌骨棕色肿瘤合并左侧下甲状旁腺腺瘤。左侧上、下甲状旁腺切除术,下颌骨节段切除加钛电镀。面部骨骼棕色肿瘤是一种罕见的肿瘤。极少数情况下,它会达到巨大的尺寸,导致出血。虽然甲状旁腺切除术和矫正甲状旁腺激素水平会导致小肿瘤的消退,但有并发症的大棕色肿瘤应通过手术切除和重建来处理。
{"title":"Large Brown Tumour of Mandible with Bleeding as Initial Presentation: A Case Report.","authors":"Ajinkya Pawar, Priyank Rathod, Jebin Aaron, Vivek Bande, Kanika Kapur","doi":"10.1007/s12070-023-04003-w","DOIUrl":"10.1007/s12070-023-04003-w","url":null,"abstract":"<p><p>Brown Tumour or Osteitis fibrous cystic or Von-Recklinghausen disease of bone is a non-malignant condition due to abnormal metabolism of bones in hyperparathyroidism. Although pathognomonic of hyperparathyroidism, brown tumours are rare and only case reports are found in literature. We report a case of brown tumour of mandible with recurrent episodes of bleeding. A 46 year old male patient presented in emergency with bleeding from ulceroproliferative mass from left floor of mouth. After control of bleeding, radiological, laboratory and histopathological investigations were done that led to the diagnosis of brown tumour of mandible in the presence of parathyroid adenoma of left lower parathyroid gland. Left upper and lower parthyroidectomy was done with segmental resection of mandible with mass and titanium plating. Brown tumour of facial bones is a rare entity. Very rarely it can reach enormous sizes to cause bleeding. Although parathyroidectomy and correction of parathormone levels cause regression of small tumours, large brown tumours with complications should be managed with surgical resection and reconstruction.</p>","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":"25 1","pages":"3988-3992"},"PeriodicalIF":0.6,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646025/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86954982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
uGI: Biomaker-Cut-Offs in der Immunonkologie uGI:免疫肿瘤学中的生物标记物临界值
IF 2.4 4区 医学 Q3 ONCOLOGY Pub Date : 2023-12-01 DOI: 10.1159/000535307
{"title":"uGI: Biomaker-Cut-Offs in der Immunonkologie","authors":"","doi":"10.1159/000535307","DOIUrl":"https://doi.org/10.1159/000535307","url":null,"abstract":"","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":"95 ","pages":"531 - 532"},"PeriodicalIF":2.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139014148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HCC - Frühzeitiges Erkennen ermöglicht rasche und effektive Therapie HCC - 早期检测可实现快速有效的治疗
IF 2.4 4区 医学 Q3 ONCOLOGY Pub Date : 2023-12-01 DOI: 10.1159/000535417
{"title":"HCC - Frühzeitiges Erkennen ermöglicht rasche und effektive Therapie","authors":"","doi":"10.1159/000535417","DOIUrl":"https://doi.org/10.1159/000535417","url":null,"abstract":"","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":"14 1","pages":"533 - 534"},"PeriodicalIF":2.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139019852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
4-Jahres-Daten der CheckMate-9LA-Studie zum NSCLC CheckMate 9LA NSCLC 研究的 4 年数据
IF 2.4 4区 医学 Q3 ONCOLOGY Pub Date : 2023-12-01 DOI: 10.1159/000535447
{"title":"4-Jahres-Daten der CheckMate-9LA-Studie zum NSCLC","authors":"","doi":"10.1159/000535447","DOIUrl":"https://doi.org/10.1159/000535447","url":null,"abstract":"","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":"52 ","pages":"535 - 536"},"PeriodicalIF":2.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139022666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sacituzumab govitecan beim fortgeschrittenen Mammakarzinom 萨妥珠单抗戈维替康治疗晚期乳腺癌
IF 2.4 4区 医学 Q3 ONCOLOGY Pub Date : 2023-12-01 DOI: 10.1159/000535408
{"title":"Sacituzumab govitecan beim fortgeschrittenen Mammakarzinom","authors":"","doi":"10.1159/000535408","DOIUrl":"https://doi.org/10.1159/000535408","url":null,"abstract":"","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":"324 2","pages":"IX - XX"},"PeriodicalIF":2.4,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139022804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum 勘误表
IF 2.4 4区 医学 Q3 ONCOLOGY Pub Date : 2023-08-29 DOI: 10.1159/000530178
{"title":"Erratum","authors":"","doi":"10.1159/000530178","DOIUrl":"https://doi.org/10.1159/000530178","url":null,"abstract":"","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":"46 1","pages":"438 - 440"},"PeriodicalIF":2.4,"publicationDate":"2023-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43009879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OnkoImmun 19 OnkoImmun 19
IF 2.4 4区 医学 Q3 ONCOLOGY Pub Date : 2023-08-23 DOI: 10.1159/000531620
Ausgabe, Dr. Claudia Schöllmann, Grasbrunn Druck
{"title":"OnkoImmun 19","authors":"Ausgabe, Dr. Claudia Schöllmann, Grasbrunn Druck","doi":"10.1159/000531620","DOIUrl":"https://doi.org/10.1159/000531620","url":null,"abstract":"","PeriodicalId":19543,"journal":{"name":"Oncology Research and Treatment","volume":" ","pages":"I - VIII"},"PeriodicalIF":2.4,"publicationDate":"2023-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46748350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Oncology Research and Treatment
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1